hotspot -WSS

hotspot

author：explore 2025-09-30 16:27:48 - browse：5

European Medicines Agency Suffers Cyber Attack in Amsterdam — Paulo Amorim / VWPics via AP Images

LONDON — European regulators on Friday reiterated their view that an ALS treatment from Amylyx Pharmaceuticals should not be approved, likely dooming the drug’s chances for now.

A European Medicines Agency committee had initially recommended against approving the drug, known as Albrioza, in June. Friday’s confirmation of that position came after the company appealed the decision. While the European Commission officially decides whether to approve a new medicine, it almost always follows the committee’s guidance. The final decision is expected to be made before the end of the year.

The drug, which won approval last year in the United States and is marketed Relyvrio, is designed to slow the progression of the fatal neurological condition. In its pivotal trial, patients who received the drug over 24 weeks scored about two points better on a 48-point scale of symptoms than those who got a placebo, indicating the drug slowed disease progression.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： David Sabatini, ex

focus

WSS

Readout LOUD podcast: A CRISPR milestone, biotech mixology

$1 billion proposal to grow Boston, Massachusetts biotech

Immune cells and nerve overgrowth may explain recurring UTI pain

Ancient Greek ideas underpin modern concepts of pregnancy

Lack of health data on LGBTQ+ people has serious consequences

Morphosys mixed study results for blood cancer drug

explore

hotspot

explore

United colonoscopy coverage change 'may cost lives,' doctors say

David Sabatini, ex

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Medicare drug price negotiation continues, as pharma counteroffers

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

U.K. considers world's first use of meningitis vaccine to address gonorrhea

Sports medicine is finally prioritizing gender equality

David Sabatini, ex

Medicare proposal to cover medical devices draws a mixed reaction

For AI in health care standards, federal regulators join with industry group

leisure time

Medicare drug price negotiation hearing pits pharma v Biden admin

Ancient Greek ideas underpin modern concepts of pregnancy

PBM reforms clear House panel

Microsoft's Peter Lee: Generative AI could help doctors be more human

The untold story of TV’s first prescription drug ad

Ozempic has benefits for kidney disease as well as diabetes

entertainment

entertainment

focus

hotspot